Javascript must be enabled to continue!
Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016
View through CrossRef
PurposeThis study investigated the incidence and relative survival rates (RSRs) for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in KoreaMaterials and MethodsData from the Korea Central Cancer Registry were used to calculate percent distributions, age-specific incidence rates, age-standardized incidence rates (ASRs) per million, annual percent changes (APCs), average APCs, and RSRs for cancers diagnosed in AYAs.Results ASR of all cancers among AYAs was 654.5 per million. The largest diagnosed group of cancers was carcinomas (almost 80%). Crude incidence increased with age, from 170.4 per million for those aged 15-19 years to 1,639.8 per million for those aged 35-39 years. ASR increased from 414.8 per million to 820.4 per million, with an APC of 9.0%. The incidence of thyroid carcinoma showed the most rapid increment (APC, 14.0%), followed by non-Hodgkin lymphoma (APC, 13.4%). The 5-year RSR among AYAs significantly improved from 62.1% to 90.8%. Survival improvement in AYAs was higher than that in children but lower than that in older adults (APC, 2.1% vs. 1.9% vs. 3.1%). The most marked survival improvement was found for leukemia and lymphoma. Astrocytoma, rhabdomyosarcoma, and carcinoma of the trachea, bronchus, and lung had a 5-year RSR of < 50%.ConclusionThere was an improvement in cancer survivals in AYAs, comparable to that achieved in children. However, survivals in several cancer types do not appear to be improving. Further research focusing on the epidemiology and therapeutic strategies for cancers in AYAs is needed.
Korean Cancer Association
Title: Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016
Description:
PurposeThis study investigated the incidence and relative survival rates (RSRs) for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in KoreaMaterials and MethodsData from the Korea Central Cancer Registry were used to calculate percent distributions, age-specific incidence rates, age-standardized incidence rates (ASRs) per million, annual percent changes (APCs), average APCs, and RSRs for cancers diagnosed in AYAs.
Results ASR of all cancers among AYAs was 654.
5 per million.
The largest diagnosed group of cancers was carcinomas (almost 80%).
Crude incidence increased with age, from 170.
4 per million for those aged 15-19 years to 1,639.
8 per million for those aged 35-39 years.
ASR increased from 414.
8 per million to 820.
4 per million, with an APC of 9.
0%.
The incidence of thyroid carcinoma showed the most rapid increment (APC, 14.
0%), followed by non-Hodgkin lymphoma (APC, 13.
4%).
The 5-year RSR among AYAs significantly improved from 62.
1% to 90.
8%.
Survival improvement in AYAs was higher than that in children but lower than that in older adults (APC, 2.
1% vs.
1.
9% vs.
3.
1%).
The most marked survival improvement was found for leukemia and lymphoma.
Astrocytoma, rhabdomyosarcoma, and carcinoma of the trachea, bronchus, and lung had a 5-year RSR of < 50%.
ConclusionThere was an improvement in cancer survivals in AYAs, comparable to that achieved in children.
However, survivals in several cancer types do not appear to be improving.
Further research focusing on the epidemiology and therapeutic strategies for cancers in AYAs is needed.
Related Results
P0897 Serum concentrations of infliximab are comparable with and without immunosuppression during subcutaneous infliximab induction treatment for Crohn’s disease
P0897 Serum concentrations of infliximab are comparable with and without immunosuppression during subcutaneous infliximab induction treatment for Crohn’s disease
Abstract
Background
Subcutaneous (SC) infliximab (IFX) is available for maintenance treatment of Crohn’s disease (CD) fol...
Rectal Cancer in Adolescent and Young Adult Patients: Pattern of Clinical Presentation and Case-Matched Comparison of Outcomes
Rectal Cancer in Adolescent and Young Adult Patients: Pattern of Clinical Presentation and Case-Matched Comparison of Outcomes
BACKGROUND:
Rectal cancer in adolescents and young adults (age ≤39) is increasing. Early diagnosis is a challenge in this subset of patients.
...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Młodociani sprawcy przestępstw przeciwko mieniu
Młodociani sprawcy przestępstw przeciwko mieniu
The new Polish penal legislation of 1969 introduced special rules of criminal liability of young adult offenders' aged 17-20. In 1972 criminological research was undertaken in orde...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...

